Beam Therapeutics (NASDAQ:BEAM) Stock Breaks Below Fifty Day Moving Average – Time to Sell?

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $25.45 and traded as low as $23.60. Beam Therapeutics shares last traded at $25.15, with a volume of 3,115,247 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Canaccord Genuity Group reduced their target price on Beam Therapeutics from $79.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. Wall Street Zen cut Beam Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. Guggenheim decreased their target price on Beam Therapeutics from $55.00 to $51.00 and set a “buy” rating for the company in a research report on Thursday, November 5th. Finally, Wedbush raised their price target on shares of Beam Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.64.

Check Out Our Latest Analysis on BEAM

Beam Therapeutics Stock Down 6.9%

The company has a debt-to-equity ratio of 0.11, a current ratio of 13.01 and a quick ratio of 13.00. The firm has a 50-day moving average price of $25.28 and a 200-day moving average price of $27.90.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.11). Beam Therapeutics had a negative return on equity of 32.76% and a negative net margin of 73.04%. The business had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $8.75 million. During the same quarter in the prior year, the firm earned ($1.10) EPS. The firm’s revenue for the quarter was down 96.8% compared to the same quarter last year. Sell-side analysts forecast that Beam Therapeutics Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO John Evans sold 25,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total value of $589,250.00. Following the completion of the sale, the chief executive officer directly owned 1,047,205 shares in the company, valued at $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Benjamin Edwards Inc. raised its position in shares of Beam Therapeutics by 7.0% in the 3rd quarter. Benjamin Edwards Inc. now owns 33,172 shares of the company’s stock worth $811,000 after acquiring an additional 2,163 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Beam Therapeutics by 94.9% during the third quarter. First Trust Advisors LP now owns 348,738 shares of the company’s stock worth $8,527,000 after purchasing an additional 169,793 shares during the period. Public Sector Pension Investment Board acquired a new stake in Beam Therapeutics during the 3rd quarter valued at approximately $3,758,000. Global Retirement Partners LLC lifted its position in Beam Therapeutics by 297.3% during the third quarter. Global Retirement Partners LLC now owns 1,490 shares of the company’s stock valued at $36,000 after purchasing an additional 1,115 shares during the period. Finally, Edgestream Partners L.P. purchased a new stake in shares of Beam Therapeutics in the third quarter worth about $5,995,000. Hedge funds and other institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

(Get Free Report)

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.

Recommended Stories

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.